The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationGain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationHematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Hellström, M., Kalén, M., Lindahl, P., Abramsson, A., & Betsholtz, C. (1999) · Development · doi:10.1242/dev.126.14.3047 · Cited by 1,700
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Self-citationTalpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Rubin, B. P., Singer, S., Tsao, C., Duensing, A. U., Lux, M. L., Ruiz, R., Hibbard, M. K., Chen, C. J., Xiao, S., Tuveson, D. A., et al. (2001) · PubMed · Cited by 959
The Design of Leadlike Combinatorial Libraries
Teague, S. J., Davis, A. M., Leeson, P. D., & Oprea, T. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19991216)38:24<3743::aid-anie3743>3.0.co;2-u · Cited by 870
Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D., Fletcher, J. A., & Demetri, G. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204704 · Cited by 695
Acute leukaemia in bcr/abl transgenic mice
Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P. K., & Groffen, J. (1990) · Nature · doi:10.1038/344251a0 · Cited by 672
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
Lux, M. L., Rubin, B. P., Biase, T. L., Chen, C.-J., Maclure, T., Demetri, G., Xiao, S., Singer, S., Fletcher, C. D. M., & Fletcher, J. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64946-2 · Cited by 642
Heinrich, M. C., Blanke, C. D., Druker, B. J., & Corless, C. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1692 · Cited by 634
Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584
Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
Self-citationInduction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Kelliher, M. A., McLaughlin, J., Witte, O. N., & Rosenberg, N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6649 · Cited by 514
le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., & Gambacorti-Passerini, C. (2000) · Blood · doi:10.1182/blood.v95.5.1758.005a41_1758_1766 · Cited by 484
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
Deininger, M. W. N., Goldman, J. M., Lydon, N., & Melo, J. V. (1997) · Blood · doi:10.1182/blood.v90.9.3691 · Cited by 482
von Bubnoff, N., Schneller, F., Peschel, C., & Duyster, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 464
Pietras, K., Östman, A., SJÖQUIST, M., Buchdunger, E., Reed, R. K., Heldin, C., & Rubin, K. (2001) · PubMed · Cited by 450
Self-citationWeisberg, E., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v95.11.3498 · Cited by 401
In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor
le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., & Gambacorti-Passerini, C. (1999) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/91.2.163 · Cited by 374
Self-citationHorita, M., Andreu, E. J., Benito, A., Arbona, C., Sanz, C., Benet, I., Prosper, F., & Fernandez-Luna, J. L. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.977 · Cited by 366
Gambacorti-Passerini, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1641 · Cited by 320
Gambacorti-Passerini, C., le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G. M., Belotti, D., et al. (1997) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.1997.0155 · Cited by 316
Delivery of Molecular Medicine to Solid Tumors
Jain, R. K. (1996) · Science · doi:10.1126/science.271.5252.1079 · Cited by 312
Kilic, T., Alberta, J. A., Zdunek, P. R., Acar, M., Iannarelli, P., O'Reilly, T., Buchdunger, E., Black, P. M., & Stiles, C. D. (2000) · PubMed · Cited by 310
Self-citationShimizu, A., O'Brien, K. P., Sjöblom, T., et al. (1999) · PubMed · Cited by 289
Sjöblom, T., Shimizu, A., O'Brien, K. P., Pietras, K., Cin, P. D., Buchdunger, E., Dumanski, J. P., Östman, A., & Heldin, C. (2001) · PubMed · Cited by 279
Self-citationOda, T., Heaney, C., Hagopian, J. R., Okuda, K., Griffin, J. D., & Druker, B. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31596-x · Cited by 272
Roots of Clinical Resistance to STI-571 Cancer Therapy
Barthe, C., Cony-Makhoul, P., Melo, J. V., & Mahon, J. R. F.-X. (2001) · Science · doi:10.1126/science.293.5538.2163a · Cited by 271
β1 Integrin-mediated collagen gel contraction is stimulated by PDGF
Gullberg, D., Tingström, A., Thuresson, A.-C., Olsson, L., Terracio, L., Borg, T. K., & Rubin, K. (1990) · Experimental Cell Research · doi:10.1016/0014-4827(90)90305-t · Cited by 270
Pharmacology of imatinib (STI571)
Buchdunger, E., O'Reilley, T., & Wood, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80600-1 · Cited by 269
Self-citationAutocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.
Krystal, G. W., Hines, S. J., & Organ, C. P. (1996) · PubMed · Cited by 266
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal, G. W., Honsawek, S., Litz, J., & Buchdunger, E. (2000) · PubMed · Cited by 265
Self-citationARG tyrosine kinase activity is inhibited by STI571
Okuda, K., Weisberg, E., Gilliland, D. G., & Griffin, J. D. (2001) · Blood · doi:10.1182/blood.v97.8.2440 · Cited by 257
Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives
Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., & Lydon, N. B. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(96)00601-4 · Cited by 247
Self-citationWang, W.-L., Healy, M. E., Sattler, M., Verma, S., Lin, J., Maulik, G., Stiles, C. D., Griffin, J. D., Johnson, B. E., & Salgia, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203698 · Cited by 234
Gesbert, F., Sellers, W. R., Signoretti, S., Loda, M., & Griffin, J. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007291200 · Cited by 220
Reinmuth, N., Liu, W., Jung, Y. D., Ahmad, S. A., Shaheen, R. M., Fan, F., Bucana, C. D., McMahon, G., Gallick, G. E., & Ellis, L. M. (2001) · The FASEB Journal · doi:10.1096/fj.00-0693fje · Cited by 214
Jousset, C., Carron, C., Boureux, A., Quang, C. T., Oury, C., Dusanter‐Fourt, I., Charon, M., Levin, J., Bernard, O., & Ghysdael, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.1.69 · Cited by 207
Involvement of platelet-derived growth factor in disease: development of specific antagonists
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)80010-5 · Cited by 202
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells
Sillaber, C., Gesbert, F., Frank, D. A., Sattler, M., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v95.6.2118 · Cited by 198
Hofmann, W.-K., de Vos, S., Elashoff, D., Gschaidmeier, H., Hoelzer, D., Koeffler, H. P., & Ottmann, O. G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07678-x · Cited by 194
Heuchel, R., Berg, A., Tallquist, M., Åhlén, K., Reed, R. K., Rubin, K., Claesson-Welsh, L., Heldin, C.-H., & Soriano, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11410 · Cited by 188
Wang, D., Huang, H., Kazlauskas, A., & Cavenee, W. K. (1999) · PubMed · Cited by 186
Nistér, M., Claesson-Welsh, L., Eriksson, A., Heldin, C. H., & Westermark, B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55365-5 · Cited by 178
Beran, M., Cao, X., Estrov, Z., Jeha, S., Jin, G., O'Brien, S. M., Talpaz, M., Arlinghaus, R. B., Lydon, N., & Kantarjian, H. M. (1998) · PubMed · Cited by 176
Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., Lydon, N., & Traxler, P. M. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00197-7 · Cited by 150
Self-citationA novel physiological function for platelet‐derived growth factor‐BB in rat dermis.
Rodt, S. Å., Åhlén, K., Berg, A., Rubin, K., & Reed, R. K. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021584 · Cited by 136
Dan, S., Naito, M., & Tsuruo, T. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400400 · Cited by 126
Tomasson, M. H., Williams, I. R., Hasserjian, R. P., Udomsakdi, C., McGrath, S. M., Schwaller, J., Druker, B. J., & Gilliland, D. G. (1999) · Blood · doi:10.1182/blood.v93.5.1707 · Cited by 108
Wolff, N. C., & Ilaria, R. L. (2001) · Blood · doi:10.1182/blood.v98.9.2808 · Cited by 102
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines
Jonuleit, T., van der Kuip, H., Miething, C., Michels, H., Hallek, M. J., Duyster, J., & Aulitzky, W. E. (2000) · Blood · doi:10.1182/blood.v96.5.1933 · Cited by 99
Jørgensen, H. G., Elliott, M. A., Allan, E. K., Carr, C. E., Holyoake, T. L., & Smith, K. D. (2002) · Blood · doi:10.1182/blood.v99.2.713 · Cited by 85
Cited by
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Metadata
- Authors
- Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-07
- Volume
- 1
- Issue
- 7
- Pages
- 493-502
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2162525969
- Cited by
- 1,389
- References
- 68
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.